This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Genta Takes Another Stab

The Qnexa data released Wednesday were impressive, especially from an efficacy standpoint, where weight loss exceeded anything seen to date by competing drugs from Arena Pharmaceuticals (ARNA) and Orexigen Therapeutics (OREX).

Qnexa will continue to be nagged by worries about safety, primarily the central nervous system side effects of topiramate.

Next up is the second phase III weight-loss study from Arena's drug lorcaserin, which should be released before the end of the month. After that, all three weight-loss drugs, Qnexa, lorcaserin and Orexigen's Contrave, will face the scrutiny of obesity doctors at the Obesity Society annual scientific meeting Oct. 24-28.

Next up, a compliment from Brad L. He writes, "Hey, I just wanted to say thank you for your great work. I'm an individual investor (my investment income is my livelihood) and I just wanted to say I find your articles to be very valuable. Biotech is such a hard thing to invest in because so few people really understand the underlying science (including me) so it is really good to read from someone who clearly gets it. There is so much hype about biotech stocks (I think because of their size and obscurity) that, truthfully, the articles of yours I find most valuable are the ones where you shoot companies down like Antigenics (AGEN). Thanks a lot for providing a professional viewpoint. I wanted you to know that there are a lot of real investors out here who really appreciate it."

Fan mail is just as fun to receive as hate mail. Thanks for the kind words, Brad, and thanks for being a reader of mine.

5 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs